Waters Corporation (WAT)
Instrumentación de laboratorio y ciencias analíticas
Leading manufacturer of liquid chromatography and mass spectrometry systems, which in February 2026 completed the transformational acquisition of Becton Dickinson's Biosciences & Diagnostic Solutions business for $16.8bn, doubling its size and adding clinical diagnostics and flow cytometry; the combined business is high quality, but the stock trades near its 52-week high at a multiple that already demands near-flawless execution of the integration and synergies, with no visible margin for error.
- Price
- $414.61
- Intrinsic value (5y, base)
- $455
- Total annual return (5y)
- 1.9%
- Status (nominal)
- Preserves value
- Margin of safety
- No margin
The essentials
- The BDS acquisition (Feb-2026, $16.8bn, Reverse Morris Trust structure) doubles revenue and adds clinical diagnostics and flow cytometry, funded with ~$4.0bn of newly assumed debt
- Second-quarter 2026 (first full quarter with BDS) beat guidance across all four divisions; the company raised full-year FY2026 guidance to revenue of $6.42-6.48bn and adjusted earnings per share of $14.45-14.65
- At ~28 times the FY2026 guided adjusted earnings, the price already pays for sustained integration execution: the Preserves value results from comparing that entry multiple against a disciplined exit multiple within the medical instrumentation band
Intrinsic value — two valuation methods
The methods disagree: one places the value today above the price ($415) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $415 trades ~13.6% above its value discounted to today (~$365); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Preserva valor: the target price ($455) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$226.
Thesis
The business
High-quality laboratory instrumentation, with a legacy business that has a reasonable moat (proprietary columns, regulatory switching costs, recurring service) that in February 2026 doubled in size by absorbing Becton Dickinson's diagnostics and biosciences business, a transformational transaction largely funded with new debt.
The valuation
Valued as a sum of the parts: the legacy instruments business (Analytical Sciences + Materials Sciences) at a multiple toward the top of the medical instrumentation band, and the acquired business (Biosciences + Advanced Diagnostics) at a multiple toward the bottom of that same band given the integration risk and the leverage assumed. The result is $455 per share at five years, against a market price of $415.
The margin of safety
No margin of safety: at this price capital is preserved, but it is not bought below its value. The Preserves value follows from comparing the current price, which already capitalizes close to 28 times FY2026 guided adjusted earnings, against a disciplined exit multiple within the sector's historical band, without extrapolating the rich entry multiple.
What to watch
The central disconfirming test is execution of the BDS integration over the next two to three years: if the company captures the projected cost synergies (~$200M) and revenue synergies (~$290M) and sustains mid-single-digit growth in the diagnostics business, the thesis improves; if the integration slips or the leverage (~$4.0bn of new debt) constrains flexibility, the margin of error the price currently offers is thin.
Educational / informational. Does not constitute investment advice.